UNSPSC 51271608: Clibucaine

This classification denotes an anesthetic agent with the molecular formula C15H20Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NB2ZOX88RR, chemically known as 2,4-dichloro-beta-piperidinobutyranilide but generally known as clibucaine, which bears US NIH Compound Identifier 65613. European Medicines Agency schedules Clibucaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06657MIG.

UNSPSC 51271608 Clibucaine is a Commodity code representing local anesthetic pharmaceutical products procured through state and local cooperative purchasing vehicles for distribution across government healthcare facilities. Recent activity shows state and local governments sourcing generic multi-source pharmaceuticals and over-the-counter products through established wholesaler networks, with pricing and product compliance as primary evaluation drivers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 seeking manufacturers to supply comprehensive pharmaceutical product lines with specific National Drug Codes, requiring vendors to work through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three authorized wholesalers, and demonstrate flexible pricing options including flat price, net price formats, or WAC-minus structures. The RFP evaluation weights price competitiveness at 75 percent, with administrative compliance, EDI capability, and pricing format adherence making up the remaining 25 percent.

MMCAP's cooperative purchasing model extends across multiple states including Minnesota and Oregon, creating a multi-jurisdiction procurement vehicle typical of regional state purchasing consortiums. The RFP response deadline was March 26, 2026, with awarded vendors provisioned to wholesalers by May 15, 2026 and resulting contracts effective July 1, 2026. Vendors must carry comprehensive insurance including $5 million commercial general liability per occurrence and $2 million network security and privacy liability, and face performance penalties ranging from $200 to $1,500 per violation for late reporting or onboarding failures. The contract term runs two years for new responders with optional extensions at MMCAP's discretion, and vendors are subject to a 3 percent administrative fee on all contract purchases. No specific award value or budget range was disclosed in the solicitation materials; MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.